H1N1 vaccine safety monitoring: beyond background rates.

摘要

Since its emergence early this year, the H1N1 2009 influenza A virus has achieved pandemic proportions. Vaccines have been produced by several manufacturers and mass-vaccination campaigns are underway in the USA and several other countries. Scrutiny of the safety of H1N1 vaccines is expected to be intense. With potentially hundreds of millions of people being vaccinated, adverse events will inevitably occur in some recently vaccinated people and the question will arise as to whether the vaccine was causative.